Home
AmoyDx

AmoyDx Market Share Analysis for August 2026

厦门艾德生物医药科技股份有限公司由郑立谋教授于2008年回国创办，集肿瘤精准医疗诊断产品的研发、生产、销售、服务为一体，同时具备三类体外诊断产品生产/经营资质及独立临床医学检验资质。

Health > Biotechnology and Pharmaceuticals

Domainamoydx.com

Year Founded--

Employees1001 - 5000

Annual Revenue$5M - $10M

AmoyDx

AmoyDx (including company regionals)

amoydx.com

See more website traffic and engagement information

AmoyDx Revenue up to August 2026 is 5M - 10M

revenue generated by AmoyDx top domains

AmoyDx top domains revenue over 3 years

Revenue for AmoyDx top domains

amoydx.com5M - 10M

See more with Sales Intelligence

Total visits to AmoyDx's top domains

Understand AmoyDx market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

amoydx.com376

See more with Sales Intelligence

Avg. visit duration in AmoyDx's top domains

Analyze AmoyDx engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

amoydx.com00:02:18

See more with Sales Intelligence

Avg. pageviews on AmoyDx's top domains

See how AmoyDx keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

amoydx.com3.36

See more with Sales Intelligence

AmoyDx top competitors by domain

Top similar sites in August 2026, ranked by their affinity

sekisuidiagnostics.comCompany NameSekisui DiagnosticsEmployees501 - 1000HQUnited States, Massachusetts, BurlingtonAnnual revenue$200M - $500MTotal visits8.2KHealth > Health - Other

Top technologies used by AmoyDx

These are the website technologies, by industry, used by AmoyDx top domains

Mobile (3)

Meta Viewport

Advertising (1)

PubMatic

Conversion & Analytics (1)

CNZZ

Email Services (1)

QQ Mail

More Technologies

4

See all

News & Signals from AmoyDx

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAmoydx is developing CDx for BRCA gene mutations in breast cancer patients.In the EU, AmoyDx and AstraZeneca are partnering to develop CDx for BRCA gene mutations in breast cancer patients.

NewsAmoydx is developing CDx in China.AmoyDx partnered with Pierre Fabre to develop a CDx in China to detect BRAF mutation in tumor samples and select patients eligible for Braftovi (encorafenib) with or without Mektovi (binimetinib).